Clinical Trials Browser

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT07283705 2026-04-16

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Phase 2 Study

NCT07294664 2026-04-16

PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer

Phase 2 Recruiting

78 enrolled

Gastrointestinal

Advanced Gastric Cancer

NCT03161522 2026-04-15

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Phase 2 Recruiting

100 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT03682289 2026-04-15

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2 Recruiting

89 enrolled

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT04486378 2026-04-15

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Phase 2 Recruiting

327 enrolled

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT04858334 2026-04-15

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Phase 2 Recruiting

152 enrolled

Gastrointestinal

Pancreatic Acinar Cell Carcinoma

NCT05065801 2026-04-15

GABRINOX2

Phase 2 Recruiting

162 enrolled

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT06638931 2026-04-15

ANTARES

Phase 2 Recruiting

28 enrolled

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT06659705 2026-04-15

INDIGO-FAPI

Phase 2 Recruiting

35 enrolled

Gastrointestinal

Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06820463 2026-04-15

AndroMETa-CRC

Phase 2 Recruiting

390 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07126158 2026-04-15

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Phase 2 Recruiting

36 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT07438106 2026-04-15

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Locally Advanced Pancreatic Cancer With KRAS G12D Mutation

NCT07519486 2026-04-15

INS-ESCC-CT

Phase 2 Recruiting

118 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07530094 2026-04-15

STELLAR01

Phase 2 Recruiting

98 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT07530445 2026-04-15

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT06880523 2026-04-14

SLIDE-HCC

Phase 2 Recruiting

140 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06885814 2026-04-14

Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07205731 2026-04-14

SAFE ESO

Phase 2 Recruiting

95 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasms

NCT07527026 2026-04-14

A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer

Phase 2 Recruiting

44 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer

NCT04550494 2026-04-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Phase 2 Recruiting

36 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04939051 2026-04-13

Obeticholic Acid for Prevention in Barrett's Esophagus

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT05257590 2026-04-13

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

Phase 2 Recruiting

95 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT05745857 2026-04-13

SLURP

Phase 2 Recruiting

25 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT06557733 2026-04-13

An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

Phase 2 Recruiting

38 enrolled

Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT07521852 2026-04-13

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Phase 2 Recruiting

200 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07042685 2026-04-09

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

Phase 2 Recruiting

50 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT07235293 2026-04-09

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Phase 2 Recruiting

90 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05624918 2026-04-08

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Phase 2 Recruiting

38 enrolled

Gastrointestinal

Pancreatic Adenocarcinoma

NCT05753306 2026-04-08

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Phase 2 Recruiting

40 enrolled

GastrointestinalOther neoplasm

Gastric Adenocarcinoma

NCT06162650 2026-04-08

Total Neoadjuvant Therapy in Rectal Cancer

Phase 2 Recruiting

42 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06728410 2026-04-08

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Phase 2 Recruiting

38 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT06760819 2026-04-08

panSOHO

Phase 2 Recruiting

111 enrolled

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT07517107 2026-04-08

Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer

Phase 2 Recruiting

600 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05184803 2026-04-07

A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer

Phase 2 Recruiting

63 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05661643 2026-04-07

GIST

Phase 2 Recruiting

29 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05905887 2026-04-07

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Phase 2 Recruiting

48 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT06326346 2026-04-07

GIST Oral Paclitaxel(Liporaxel)

Phase 2 Recruiting

28 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT07506109 2026-04-07

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Phase 2 Recruiting

49 enrolled

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT07136077 2026-04-06

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Phase 2 Recruiting

20 enrolled

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT07292298 2026-04-06

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

Phase 2 Recruiting

44 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06050252 2026-04-03

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

Phase 2 Recruiting

27 enrolled

Gastrointestinal

Resectable Intrahepatic Cholangiocarcinoma

Clinical Trials

TATE-PD1

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

ABLATE

Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy

Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

PSI-Immune

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

GABRINOX2

ANTARES

INDIGO-FAPI

AndroMETa-CRC

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

INS-ESCC-CT

STELLAR01

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

SLIDE-HCC

Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma

SAFE ESO

A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Obeticholic Acid for Prevention in Barrett's Esophagus

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

SLURP

An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Total Neoadjuvant Therapy in Rectal Cancer

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

panSOHO

Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer

A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer

GIST

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

GIST Oral Paclitaxel(Liporaxel)

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery